Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to SEQ ID No, 2 and uses thereof for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject.

Abstract: Provided herein is a polypeptide or formulation comprising a polypeptide for use in the treatment of a disease characterized by endothelial dysfunction, wherein the polypeptide or a fragment thereof comprising an amino acid comprising an amino acid sequence having at least 55% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, 2, 3, or 4. Also provided are methods and uses relating to the same.

Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to SEQ ID No. 2 and uses thereof for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject.

Abstract: Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/KI-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.

Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to one or more of SEQ ID No(s) 1, 2, 3 or 4. The therapeutically effective amount of polypeptide may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed are methods for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide according to SEQ ID Nos. 1-4.